The researchers asked a deliberately narrow question. Their endpoint was not the cure of the eye disease itself, but thyroid functional remission: resolution of the overactive thyroid state after iodine-131 therapy. Following the response categories of the 2021 Chinese Society of Nuclear Medicine guideline, which are conceptually consistent with American Thyroid Association guidance, the team classified patients as being in remission if they ended follow-up either euthyroid, with normal free thyroxine and resolution of hyperthyroid symptoms, or hypothyroid, an expected and readily managed consequence of successful radioiodine treatment. Patients whose free thyroxine remained elevated despite reduced symptoms, or whose condition failed to improve at all, were classified as not in remission. Every patient was followed for at least twelve months, and no one received antithyroid drugs, repeat iodine-131, thyroid surgery or immunosuppressive therapy during that window, ensuring that the outcome reflected the effect of the initial treatment alone.

The headline finding is striking. Among the 31 patients who reported sleeping less than six hours per night before therapy, not a single one achieved thyroid functional remission — a remission rate of zero, with a 95 percent confidence interval stretching only from 0 to 9.2 percent. At the other end of the sleep spectrum, the picture reversed dramatically: of the 37 patients reporting eight hours of nocturnal sleep, 30, or 81.1 percent, ended follow-up in remission. At seven hours, 20 of 43 patients remitted, and at six hours only 3 of 39 did. No patient in the cohort reported more than eight hours of sleep. Viewed as a gradient, the unadjusted remission rates climb from complete absence below six hours to a plateau above seven, forming one of the sharpest sleep-outcome associations reported in the radioiodine literature.

To move beyond raw rates, the team deployed a sequence of statistical techniques designed for messy clinical data. They began by screening fourteen clinical variables with univariate logistic regression, applying Benjamini–Hochberg false discovery rate correction to guard against spurious findings. Four variables survived: duration of Graves’ disease, duration of the eye disease, nocturnal sleep duration and the Clinical Activity Score, a standard seven-point measure of orbital inflammatory activity developed by the European Group on Graves’ Orbitopathy. These candidates then entered a least absolute shrinkage and selection operator, or LASSO, regression — a penalized technique that systematically shrinks weak predictors to zero — with the penalty chosen by cross-validation and the conservative one-standard-error rule. Across fifty repeated cross-validation runs, sleep duration and the Clinical Activity Score were retained in every single run, while Graves’ disease duration appeared in 64 percent of runs. The final model retained three predictors: Graves’ disease duration, sleep duration and the Clinical Activity Score.

The numbers from the post-selection model are eye-catching. Each additional hour of pretreatment nocturnal sleep was associated with roughly a six-fold increase in the odds of remission, with an odds ratio of 6.13 and a 95 percent confidence interval of 3.16 to 11.91. Each additional point on the Clinical Activity Score was associated with a 36 percent reduction in the odds of remission, with an odds ratio of 0.64. Graves’ disease duration, by contrast, was no longer statistically significant once the other two variables were accounted for. Because the model was fitted in the same sample used for variable selection, the authors are careful to label these as post-selection estimates. They also ran a Firth bias-reduced logistic regression, a technique built for situations where the outcome is nearly perfectly separated by a predictor — precisely what happens below six hours of sleep — and the sleep odds ratio attenuated only modestly, to 5.64. A further sensitivity model adjusting for age, sex and smoking left the estimates materially unchanged, as did excluding the fifteen participants younger than eighteen years.

The relationship with the Clinical Activity Score turned out to be more complicated than a straight line. Using restricted cubic splines — flexible curves that can model non-linear dose–response relationships without imposing arbitrary cut-offs — fitted simultaneously for sleep and the score, the team found that the score’s association with remission departed significantly from linearity, with a non-linearity P value below 0.001 that persisted regardless of how many knots the spline used. The sleep curve, by contrast, remained consistent with a linear association, with a non-linearity P value of 0.585. An exploratory two-piecewise analysis searching for inflection points identified a maximum-likelihood break at four points on the score: below that value, each additional point was associated with sharply reduced odds of remission, while above it the direction reversed — though that high-score segment contained only 25 patients and a very wide confidence interval, and the authors attribute the reversal to possible confounding by intensified treatment rather than any genuine protective effect of severe inflammation.

Why might sleep matter for a thyroid treatment? The biological logic is plausible. Sleep and the immune system are deeply intertwined: sleep deprivation promotes inflammatory signaling, alters cytokine production and dysregulates innate immunity, processes documented extensively in the immunology literature. Orbital fibroblasts in Graves’ disease co-express the thyrotropin receptor and the insulin-like growth factor-1 receptor, driving the inflammation, hyaluronic acid deposition and fat expansion that characterize the eye disease. Adequate sleep might, in principle, temper the autoimmune milieu that radioiodine therapy must overcome. But the authors are equally candid about the alternative explanation, which may be the more likely one: hyperthyroidism itself destroys sleep. Thyrotoxicosis is a recognized cause of sleep dysfunction, and in one series summarized in a recent review, 66.4 percent of patients with Graves’ disease reported difficulty falling asleep. Short reported sleep may therefore mark more severe thyrotoxicosis rather than acting as an independent causal factor. Notably, baseline free triiodothyronine, free thyroxine and thyrotropin receptor antibody levels were similar between the remission and non-remission groups, which only partly addresses this concern, because thyroid volume, radioiodine uptake and administered activity — the true determinants of the absorbed dose — were not available for modeling.

The study’s limitations are substantial and the authors enumerate them with unusual thoroughness. Sleep was self-reported at only six discrete values, rounding is likely, and the complete absence of remission below six hours inflates the continuous odds ratio despite Firth attenuation. The administered iodine-131 activity followed a uniform institutional protocol of 70 to 120 microcuries per gram of thyroid tissue, but protocolized dosing does not eliminate confounding, since thyroid volume and uptake determine the absorbed dose and vary across patients. Twenty patients with more severe eye disease received prednisone before therapy, discontinued at least three days prior, and this glucocorticoid pretreatment was not modeled — although the Clinical Activity Score was assessed before any steroid intervention, making steroid-indication confounding an unlikely primary explanation for the score association. The retrospective, single-center design means the findings cannot establish causality, and the fitted inflection points are explicitly labeled exploratory post hoc observations, not validated clinical thresholds. The study also cannot inform the ocular prognosis of the eye disease after therapy, since post-therapy eye status was not systematically graded, though ocular symptoms were recorded as progressed in 37 patients, or 24.2 percent of the cohort.

What remains is a provocative and internally consistent signal. Longer pretreatment nocturnal sleep and a lower Clinical Activity Score were associated with thyroid functional remission after radioactive iodine therapy, with directions that held across Firth bias reduction, adjustment for age, sex and smoking, and exclusion of minors. The authors emphasize that these associations require prospective validation in studies that record objective sleep measures, charted administered activity and dosimetry covariates, with outcomes and assessment schedules defined in advance. Until then, the data cannot show that extending sleep improves treatment response, and clinical decisions should continue to follow established European Group on Graves’ Orbitopathy guidance. But for a disease in which millions of patients undergo radioiodine therapy each year, the idea that a good night’s sleep before the dose might matter — whether as cause or as marker — is a question now firmly on the research agenda, and one that prospective studies will need to answer before any sleep target can be recommended.

Subject of Research: Nocturnal sleep duration, clinical activity score, and thyroid functional remission after radioactive iodine therapy in Graves’ disease with thyroid-associated ophthalmopathy

Article Title: Nocturnal sleep duration, clinical activity score, and thyroid functional remission after radioactive iodine therapy in Graves’ disease with thyroid-associated ophthalmopathy

Article References: Liao, K., Wei, X., Chen, Y., Meng, D., Mo, S., Sun, Z., Song, F., Lu, L., & Huang, W. (2026). Nocturnal sleep duration, clinical activity score, and thyroid functional remission after radioactive iodine therapy in Graves’ disease with thyroid-associated ophthalmopathy. Frontiers in Endocrinology, 17, Article 1954035. https://doi.org/10.3389/fendo.2026.1954035

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1954035

Keywords: Nocturnal, sleep, duration, clinical, activity, score, thyroid, functional, remission, radioactive, iodine, therapy

The study, published in Frontiers in Ophthalmology by oculoplastic surgeons at Kahana Oculoplastic and Orbital Surgery and Corewell Health William Beaumont University Hospital Eye Institute, included 36 patients with active thyroid eye disease, defined by a Clinical Activity Score of at least 3, who underwent single or staged orbital decompression between February 2023 and September 2025. Fourteen of them had preoperative dysthyroid optic neuropathy, the vision-threatening complication that has traditionally justified urgent surgery regardless of disease phase. The remaining 22 underwent decompression for indications that conventional practice would have deferred: retrobulbar pain, disfiguring proptosis with exposure keratopathy, or restrictive strabismus.

The results were striking. Mean Clinical Activity Score fell from 4.7 to 1.6, a reduction of 3.1 points with a 95 percent confidence interval of -3.92 to -2.36, well clear of zero. Mean proptosis, measured by Hertel exophthalmometry, dropped from 22.7 millimeters to 19.7 millimeters, a 3.0-millimeter reduction with a confidence interval of -3.28 to -2.23. Only one patient, a 2.8 percent rate, met the study’s definition of postoperative worsening, a two-point or greater increase in Clinical Activity Score at least eight weeks after surgery. No patients developed new-onset diplopia, a feared complication of orbital surgery, and many patients with preexisting double vision actually improved.

The technical innovation at the heart of the study is the combination of apical orbital decompression with a standardized intraorbital corticosteroid injection. During every lateral wall decompression, the surgeons contoured the deep sphenoid bone using ultrasonic aspiration and stereotactic navigation, excised intraconal fat with a median volume of 1.25 milliliters, and injected 1 milliliter of a 1:1 mixture of triamcinolone 40 milligrams per milliliter and dexamethasone 4 milligrams per milliliter into the lacrimal gland and surrounding orbital fat. The injection is considered an integral component of the operative technique rather than an optional adjunct, designed to deliver anti-inflammatory and anti-congestive effects directly at the surgical site alongside the mechanical decompression.

The rationale for targeting the orbital apex reflects a contemporary understanding of thyroid eye disease physiology. The condition is an autoimmune orbitopathy in which immune cells and cytokines stimulate orbital fibroblasts and adipocytes through thyroid-stimulating hormone receptor and insulin-like growth factor-1 receptor signaling, driving glycosaminoglycan deposition, fat expansion, and fibrosis. Active disease involves not just inflammation but significant orbital congestion from expanded fat and muscle, and congestion can cause tissue hypoxia that contributes to fibrotic remodeling. The authors argue that decompression at the apex, the primary site of venous outflow, restores drainage, reduces orbital pressure, and may even hasten resolution of inflammation, making surgery beneficial during the active phase rather than harmful.

The authors postulate that the traditional caution against operating during active disease originated in an era of anterior decompression techniques that failed to adequately address venous outflow at the orbital apex. In that context, postoperative edema and inflammation could compound preexisting congestion and produce poor outcomes. Modern techniques that contour the deep sphenoid diploe, open the posterior ethmoid, and remove the orbital process of the palatine bone all target the apex, and the study found that active inflammation did not meaningfully contribute to operative blood loss or technical difficulty. Intraoperative bleeding arose predominantly from perforating diploic venous channels within the greater wing of the sphenoid rather than from inflamed orbital soft tissue.

Because contemporary thyroid eye disease management frequently includes systemic corticosteroids and insulin-like growth factor-1 receptor inhibitors such as teprotumumab, the researchers prespecified strict endpoint rules to prevent medical therapy from artificially lowering postoperative scores. Endpoint Clinical Activity Score was defined as the last recorded value at least eight weeks after decompression, or the final score immediately before initiation of any postoperative disease-modifying therapy, with a steroid washout period of at least twelve weeks when applicable. Under these rules, outcomes were consistent regardless of perioperative medical treatment: patients without preoperative disease-modifying therapy showed a mean Clinical Activity Score reduction of 2.8 and proptosis reduction of 3.2 millimeters, while those with prior therapy showed reductions of 2.7 and 2.2 millimeters respectively, differences that were not clinically meaningful.

A post hoc analysis focused on the 12 patients whose primary surgical indication was retrobulbar pain or pain with eye movement, the subgroup most directly challenging the traditional timing doctrine. In these patients, mean Clinical Activity Score decreased from 4.9 to 1.7, a reduction of 3.3 points, and mean proptosis fell from 22.4 to 19.6 millimeters. None of the 12 met criteria for postoperative worsening, developed new-onset diplopia, or experienced a major surgical complication. Five patients, 41.7 percent, received postoperative disease-modifying therapy, but the authors note that in both early and late escalation groups, Clinical Activity Score had already improved before any adjunctive treatment, supporting that the combined decompression-injection approach delivered genuine clinical benefit.

The single patient who met postoperative worsening criteria illustrates the complexity of interpreting flares in a relapsing-remitting condition. She was a 73-year-old woman with severe, recurrent thyroid eye disease dating back to her hyperthyroid diagnosis in the 1960s, with persistently elevated thyroid-stimulating immunoglobulin levels. Her score had fallen to 1 by postoperative month five, but at month eight she developed a third flare-up with a score of 7, coinciding with thyroid hormone instability and rising antibody titers. Given the delayed timing and concurrent thyroid dysfunction, the authors attribute the episode to persistent autoimmunity rather than a response to the surgery itself.

The study has limitations inherent to its retrospective, single-center design. The sample was modest, and the absence of an untreated, injection-only, or inactive-phase control group means the observed improvements cannot be definitively attributed to decompression, the corticosteroid injection, patient selection, or the natural course of the disease. The universal administration of the intraorbital injection also means the individual contributions of mechanical decompression and corticosteroid cannot be disentangled within this dataset. The Clinical Activity Score captures both inflammatory and congestive signs, so some patients may have had predominantly congestive rather than immunologically active disease, which could have favorably influenced the response. Still, the authors argue that randomized prospective surgical trials are not feasible in this context, and that the evidence base for orbital surgery must rely on well-characterized retrospective cohorts. Their findings suggest that active disease alone should not automatically preclude surgery in carefully selected patients with disabling symptoms, though larger cohorts stratified by surgical indication are needed before broader adoption can be recommended.

Subject of Research: Ophthalmology

Article Title: Orbital decompression with intraorbital corticosteroid injection during the active phase of thyroid eye disease: outcomes in a real-world cohort

Article References: Neuhouser, A. J., Skender, S., Spadaro, J. Z., & Kahana, A. (2026). Orbital decompression with intraorbital corticosteroid injection during the active phase of thyroid eye disease: outcomes in a real-world cohort. Frontiers in Ophthalmology, 6, Article 1935053. https://doi.org/10.3389/fopht.2026.1935053

Image Credits: AI Generated

DOI: 10.3389/fopht.2026.1935053

Keywords: thyroid eye disease, orbital decompression, Graves orbitopathy, intraorbital corticosteroid injection, Clinical Activity Score, dysthyroid optic neuropathy, proptosis, orbital apex, teprotumumab, IGF-1R inhibitor, oculoplastic surgery, Frontiers in Ophthalmology

A new study published in the European Journal of Nuclear Medicine and Molecular Imaging suggests that a hybrid imaging technique may finally bring quantitative rigor to this assessment. Researchers at Peking Union Medical College Hospital in Beijing prospectively enrolled 33 patients with thyroid-associated ophthalmopathy and scanned them on an integrated PET/MRI system using a radiotracer called 18F-NOTA-FAPI-04. Unlike conventional FDG, which tracks glucose metabolism in any active cell, FAPI tracers bind to fibroblast activation protein, a molecule displayed by activated fibroblasts and their inflammatory partners. Because thyroid eye disease is fundamentally a fibroinflammatory disorder of the orbital tissues, the tracer offers a way to visualize the cellular machinery driving the disease rather than its downstream anatomical consequences.

The technical logic of the study is worth unpacking. Each patient’s orbits were imaged simultaneously with PET, which quantifies molecular uptake, and with a battery of advanced MRI sequences that probe tissue microstructure. The MRI panel included T2 mapping, which reflects tissue water content and therefore edema; intravoxel incoherent motion diffusion imaging, which separates true water diffusion from blood flow within capillaries; and diffusion kurtosis imaging, which captures deviations from simple Gaussian diffusion and thus hints at tissue complexity. From these sequences the team extracted parametric maps of normalized T2 signal, the heterogeneity index alpha, the distributed diffusion coefficient, the diffusion coefficient, relative blood flow, mean diffusivity, and mean kurtosis. The goal was to see whether the molecular signal from PET and the microstructural signal from MRI tell the same story, and whether combining them outperforms either alone.

Participants were classified using the Clinical Activity Score, with eyes scoring three or higher considered active and those below three considered inactive. At the patient level, a person was labeled inactive only if both eyes were inactive. The researchers then extracted a rich set of quantitative features from each eye: PET metrics including maximum and mean standardized uptake values, metabolic tumor volume, and total lesion FAPI uptake, plus first-order histogram statistics such as mean, skewness, and kurtosis from each MRI parametric map. A support vector machine, a standard machine-learning classifier, was trained to distinguish active from inactive disease, and performance was evaluated with receiver operating characteristic analysis.

Reliability came first, and the numbers were reassuring. Interobserver and intraobserver agreement in delineating the orbital regions of interest was strong, with Dice similarity coefficients of 0.850, 0.880, and 0.901 for the different comparisons. Every quantitative PET and MRI parameter showed excellent reproducibility, with intraclass correlation coefficients above 0.907. In a field where subjective eyeballing of scans has long been the norm, this level of measurement stability matters: it means the features being fed into the classifier are not artifacts of who happened to draw the contours.

The correlation analysis produced one of the study’s most interesting nuances. At the patient level, where both eyes are averaged together, PET and MRI features correlated only weakly. But when each eye was analyzed as its own unit, the correlations strengthened considerably, particularly between PET uptake metrics and features derived from T2 mapping, the heterogeneity index, the diffusion coefficient, and mean diffusivity. This asymmetry makes biological sense. Thyroid eye disease is notoriously asymmetric, with one eye often far more inflamed than the other, and averaging across eyes dilutes the very signals that matter. The finding is a quiet argument for eye-level, rather than patient-level, imaging assessment in orbital disease.

The group comparisons confirmed that several quantitative features separate active from inactive disease. At the eye level, mean standardized uptake value, metabolic tumor volume, and total lesion FAPI uptake were all significantly higher in active eyes, while maximum standardized uptake value alone showed no significant difference, a reminder that peak values are often less informative than volume-weighted averages. On the MRI side, features from T2 mapping, the heterogeneity index, the diffusion coefficient, mean diffusivity, and mean kurtosis also differed significantly between active and inactive groups, consistent with the idea that active disease carries more edema and altered diffusion characteristics than fibrotic, quiescent tissue.

When it came to discriminating activity, the combined approach won. Among single PET parameters, mean standardized uptake value performed best at the patient level with an area under the curve of 0.759, while metabolic tumor volume led at the eye level with an AUC of 0.767. These are respectable but unremarkable figures, in the range of many clinical biomarkers. The combined PET/MRI model, however, pushed performance to an AUC of 0.844 at the patient level and 0.859 at the eye level. The improvement over either modality alone indicates that FAPI uptake and MRI-derived microstructural features carry complementary, not redundant, information about the state of the orbital tissues. In practical terms, the PET signal appears to capture the cellular fibroinflammatory process while the MRI parameters capture its tissue-level consequences, and the classifier benefits from having both.

The clinical implications are significant. Treatment for active thyroid eye disease, including high-dose glucocorticoids and newer targeted agents such as anti-IGF-1 receptor antibodies, works best early in the inflammatory phase and offers little once fibrosis has set in. Conversely, rehabilitative surgeries are best deferred until the disease is inactive. A quantitative imaging biomarker that reliably separates these phases could spare patients from ineffective treatment, reduce exposure to steroid side effects, and help time interventions more precisely. It could also serve as an objective endpoint in clinical trials, where the Clinical Activity Score’s known inter-observer variability has long complicated the interpretation of results. Prior studies have explored FDG-PET and multiparametric MRI separately for this purpose, but the FAPI tracer’s specificity for activated fibroblasts, combined with simultaneous MRI acquisition on a single scanner, represents a meaningful step forward in what the field calls molecular-radiological phenotyping.

Cautions remain, and the authors are candid about them. Thirty-three patients is a small cohort, and the classifier’s performance will need validation in larger, independent, and ideally multi-center populations before it can influence routine care. The Clinical Activity Score itself, used here as the reference standard, is an imperfect ground truth, which means the imaging model is being trained to reproduce a clinical judgment rather than to measure disease biology directly. The study was registered as a clinical trial and conducted under ethics approval at Peking Union Medical College Hospital, and the team notes that further validation is required. Still, the trajectory is clear: a single integrated scan that fuses molecular information about fibroblast activity with quantitative maps of tissue edema, perfusion, and diffusion could transform thyroid eye disease from a condition assessed by counting symptoms into one measured, monitored, and treated on the basis of what is actually happening inside the orbit. For a disease that can quietly steal sight, that kind of clarity cannot come soon enough.

Subject of Research: Quantitative assessment of disease activity in thyroid-associated ophthalmopathy using integrated 18F-NOTA-FAPI-04 PET/MRI

Article Title: Integrated 18F-NOTA-FAPI-04 PET/MRI for quantitative assessment of disease activity in thyroid-associated ophthalmopathy

Article References: Yang, X., Gan, L., Shi, X., Wu, M., Li, E., Zhang, Y., Hao, Z., Huang, Z., Xing, H., Liu, X., & Huo, L. (2026). Integrated 18F-NOTA-FAPI-04 PET/MRI for quantitative assessment of disease activity in thyroid-associated ophthalmopathy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08157-x

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08157-x

Keywords: thyroid-associated ophthalmopathy, thyroid eye disease, PET/MRI, 18F-NOTA-FAPI-04, fibroblast activation protein, Clinical Activity Score, multiparametric MRI, intravoxel incoherent motion, diffusion kurtosis imaging, radiomics, support vector machine, Graves orbitopathy